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1. INTRODUCTION 
1.1. Cutaneous vasculitis and its classification 
The term vasculitis denotes inflammation of the blood vessel wall, which can occur in 
any organ system of the human body. In terms of blood vessel involvement, a stratification 
can be made in accordance whether the vasculitis affects the small, medium and the large-
sized vessels of the arterial and/or the venous systems. Notably, certain vasculitides may 
have multiple vessel-type and/or size involvements resulting in a heterogenous clinical 
manifestation, often making the diagnostic process difficult. The very first International 
Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC) was conducted 
in 1994. Since then, several advances have been made with regards to understanding the 
pathophysiological processes behind each vasculitis, which is reflected by the addendum to 
the CHCC held in 2012, where the discussion of skin-limited or skin-dominant forms was 
also necessitated (Table 1) (1). Additionally, the CHCC work group's definition of skin also 
includes the subcutaneous layer (therefore incorporating the medium vessels as well) and 
the mucosa, further widening the disease spectrum.  
Vasculitis of the skin (cutaneous vasculitis) may be categorized into three different 
disease forms: 1) skin component of a systemic vasculitis (e.g., skin symptoms of a systemic 
IgA vasculitis); 2) skin-limited form of a systemic vasculitis (e.g., skin-limited IgA 
vasculitis); and 3) single-organ vasculitis of the skin (e.g., cutaneous polyarteritis nodosa). 
While the latter does not evolve into a systemic form of vasculitis, skin-dominant variants 
may do so. It should be noted however, that nonspecific symptoms of systemic inflammatory 
processes, such as elevated inflammatory markers, leukocytosis or arthralgia do not 
necessarily establish sufficient indication for the presence of a systemic involvement of said 
vasculitis. Hence, proper exclusion of the presence of clinically detectable non-cutaneous 
organ involvement is required to conclude whether the patient truly has a skin-limited 
vasculitis or a single-organ vasculitis of the skin.  
Cutaneous vasculitides are characterised by inflammation of either the small vessels 
(including arterioles, capillaries and postcapillary venules) in the superficial and mid dermis 
and/or the medium-sized vessels (including smaller arteries and veins) located in the deep 
dermis or subcutaneous fat tissue. This locality of inflammation thus determines both the 
clinical and histopathological presentation of said vasculitides. Additional features, such as 
the presence or absence of systemic involvement, the quality of the immunoglobulin 
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Skin involvement status 
CHCC2012 
vasculitis category, name 
Cutaneous component 
of systemic vasculitis 
Skin-limited or 
skin-dominant 
variant 
Large vessel vasculitis 
Takayasu arteritis No No 
Giant cell arteritis Rare No 
Medium vessel vasculitis 
Polyarteritis nodosa Yes Yes 
Kawasaki disease No No 
Small vessel vasculitis 
Microscopic polyangiitis Yes Yes 
Granulomatosis with polyangiitis Yes Yes 
Eosinophilic granulomatosis with polyangiitis Yes Yes 
Anti-glomerular basement membrane disease No No 
IgA vasculitis (Henoch-Schönlein) Yes Yes 
Hypocomplementemic urticarial vasculitis 
(anti-C1q vasculitis) 
Yes Yes 
Variable vessel vasculitis 
Behcet’s disease Yes Yes 
Cogan’s syndrome Rare No 
Vasculitis associated with systemic disease 
SLE, rheumatoid arthritis, sarcoidosis, etc. Yes Yes 
Vasculitis associated with probable etiology 
Drugs, infections, sepsis, autoimmune diseases, 
etc.  
Yes Yes 
Cutaneous SOV (not included in CHCC2012) 
IgM/IgG vasculitis No (not observed yet) Yes (as SOV) 
Nodular vasculitis (erythema induratum of Bazin) No Yes (as SOV) 
Erythema elevatum et diutinum No Yes (as SOV) 
Hypergammaglobulinemic macular vasculitis  No Yes (as SOV) 
Normocomplementemic urticarial vasculitis No Yes (as SOV) 
Table 1. Skin involvement status by vasculitis category and disease 
CHCC2012, 2012 revised International Chapel Hill Consensus Conference Nomenclature 
of Vasculitides; SLE, systemic lupus erythematosus; SOV, single-organ vasculitis. 
Reproduced from reference (1). 
7 
 
deposition found with direct immunofluorescence staining and the presence of antineutrophil 
cytoplasmic antibodies add further criteria to be considered. 
While multiple subclassifications are possible, the two major pathophysiological 
variants are antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and immune 
complex-mediated vasculitis. As the clinical manifestations of ANCA-associated 
vasculitides show great heterogeneity, they may further be categorized based on their unique 
epidemiologic, pathologic and clinical features, in addition to their immunoserological 
findings, such as the presence of anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase 
antibodies (anti-MPO). 
Immune complex vasculitides -as the name entails- are mediated by immune 
complexes, which first form in the presence of antigen and then later precipitate in antigen 
excess. Immune complex deposition primarily takes place in the dermal postcapillary 
venules, where inflammation is induced through the activation of the complement cascade, 
resulting in mast cell degranulation and neutrophil chemotaxis, thus it can also be 
histopathologically characterized as leukocytoclastic vasculitis. Cutaneous symptoms 
usually develop a week after antigen exposure, in the form of palpable purpuras, 
erythematous papules, vesicles or urticas. Additional symptoms may also include fever, 
myalgia, weight loss, arthralgia, arthritis or various internal organ involvements (e.g.: 
genitourinary, renal, gastrointestinal and neurologic involvement) (2). In systemic 
vasculitides, the signs of organ involvement often precede the development of the cutaneous 
symptoms, ranging from as short as a few days to as long as years (3). Proper skin biopsy 
sampling of the inflamed vessels increases the diagnostic yield, where the ideal timespan of 
the fresh cutaneous lesions is within the first 24 to 48 hours of its appearance. In the majority 
of cases a punch biopsy may suffice, however an incisional biopsy may be preferred, if the 
clinical manifestations suggest the involvement of the deeper, medium-sized vessels, such 
as in the appearance of necrosis or ulceration. The classic, initial histologic findings show 
leukocytoclastic vasculitis with the infiltration of the vessel walls (predominantly in the 
postcapillary venules) by neutrophils, leukocytoclasia (fragmentation of neutrophils, 
resulting in nuclear dust) and extravasation of erythrocytes. As the inflammation progresses, 
the histopathologic feature is later characterized by mononuclear infiltrate. Direct 
immunofluorescent staining of the cutaneous biopsy specimen shows deposition of either 
C3, IgA, IgG and/or IgM in a granular pattern within the vessel walls. The highest chance 
of detecting immunoglobulin deposition is performing a biopsy from a lesion that is present 
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withing the first 48 hours. Of note, the evolution of the vasculitis may alter the qualitative 
features of direct immunofluorescent findings and can also result in its negativity (3). Hence, 
biopsy from a fresh lesion is essential for proper diagnostic workup. A key example for this 
was within the 2012 revised CHCC, where the denomination “Henoch-Schönlein purpura” 
was replaced by the term “IgA vasculitis”, owing to the compelling data indicating that IgA 
deposition proposes a unique pathophysiological feature of this vasculitis, segregating it 
from other immune complex-mediated forms. 
1.2. Immunoglobulin A vasculitis and its systemic involvement 
Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, 
is an immune complex-mediated small-vessel leukocytoclastic cutaneous vasculitis, 
characterized by palpable purpura, accompanied by arthralgia or arthritis, gastrointestinal 
(GI) and renal involvement (also known as the “classic triad” of IgAV) (4). While the exact 
cause of the disease is unknown, it is evident that the IgA system has a key role in its 
pathophysiology, as serum IgA1 level elevation have been demonstrated in patients, owing 
to the increase in their production, disturbance in their clearance and their aberrant 
glycosylation (5,6). In most cases, the symptoms are usually benign and self-limiting in the 
acute stage, which can even resolve spontaneously, without a therapeutic intervention. 
However, in a small percentage of patients, severe systemic involvement may develop and 
life-threatening complications may occur, requiring aggressive treatment modalities. 
Cutaneous symptoms in the form of palpable purpura is nearly always apparent in IgAV 
patients, which are more commonly localized to the pressure areas, particularly around the 
ankle regions. In terms of joint involvement, arthralgia most frequently affects the knees and 
the ankles, likely due to the high pressure in the venule complexes associated with the 
production of the synovial fluid, thus allowing for a favorable flow kinetic for the immune 
complex deposition. GI involvement may precede the onset of purpuras, presenting with 
colicky abdominal pain and/or GI bleeding. These symptoms are cause by bowel ischemia 
and oedema, which may further proceed into infarction or perforation. Renal involvement 
occurs in approximately 40-50% of patients, presenting with microscopic hematuria, which 
may be accompanied by proteinuria. Of note, nephritis may have a prolonged development 
timespan, compared to the cutaneous lesions, and can also be clinically detectable within 3-
6 months as well. The distinction between IgAV with nephritis and IgA nephropathy should 
be made, despite their clinical similarities. Both entities are characterized by hematuria, 
proteinuria and immune complex deposition in the glomerular mesangium. The main 
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differentiator for the two is that while IgA nephropathy is restricted specifically to the 
kidneys, IgA with nephritis is part of the clinical spectrum of a systemic involvement (7). 
IgAV is often regarded as a disease of childhood with an annual incidence rate of 3-
26.7/100.000, but contrary to popular belief, it is not uncommon in adults (6,8). Although it 
is considered to be the same entity, the clinical manifestations and disease course differ 
greatly in these two age groups. Previous studies have demonstrated that unlike in children, 
adult patients develop systemic involvement more frequently, with a high risk of severe GI 
bleeding and chronic kidney disease (9,10). This highlights the importance and the need of 
prognostic markers that can help identify IgAV patients who are at risk of developing 
unfavorable extracutaneous manifestations.  
While predictive factors have been extensively studied in children, there is limited data 
on adults (11–13). Blood neutrophil-to-lymphocyte ratio (NLR) is an inexpensive and easily 
obtainable laboratory marker for quantifying systemic inflammation, which has been used 
to predict clinical outcomes in patients with various internal malignancies, cardiovascular 
disease and liver cirrhosis (14–18). NLR is defined by the absolute number of neutrophils 
divided by the absolute number of lymphocytes. Neutrophilia is often accompanied with 
lymphocytopenia, indicating a decreased cell-mediated adaptive immune response. As this 
ratio integrates information on two immune pathways, it may provide a predictive ability 
that outweighs other inflammatory parameters. Despite the strong prognostic potential of 
NLR in the aforementioned diseases, particularly in certain malignancies, no biopsy-proven 
IgAV studies have been conducted among the adult population. In this matter, if NLR 
harbors adequate prognostic potential in IgAV, it may serve as not only a valuable biomarker 
in clinical decision making but a tool for patient risk stratification.  
1.3. Cutaneous vasculitis and vasculopathy 
In addition to the stratification of a “skin-limited” variant from a “systemic vasculitis 
with a skin component”, another subject arises. In clinical practice, distinguishing vasculitis 
from vasculopathy is also a constant challenge, often leaving one contemplating whether 
thrombosis was secondary to the inflammation of the blood vessels or vice versa. Although 
current knowledge advocates segregation by means of histopathological examination, it may 
not grasp the whole underlying pathomechanisms, due to disease evolution, which may also 
explain the discrepancy seen in the literature regarding this question. Hence, one might 
consider the notion that owing to such underlying dynamic pathomechanisms, both vasculitis 
and vasculopathy may complementarily coincide with one another, and that diagnostic 
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stratification based on histopathology alone may not grasp the full scope of the condition at 
hand. As such, rather than segregating thrombosis and inflammation, we should perhaps 
consider them as integrants of a framework, encompassing both vasculitis and vasculopathy; 
a phenomenon which has previously been observed in other entities (19,20). Of peculiar 
interest, livedoid vasculopathy (LV) and cutaneous polyarteritis nodosa (CPAN) stand in the 
precipice of such a differential diagnostic challenge, where histopathology provides the 
distinction between the two entities.  
Livedoid vasculopathy is an uncommon skin disease, characterized by focal vascular 
occlusions in the form of non-inflammatory thrombosis of the dermal venules, resulting in 
ulcerations and Milian’s atrophie blanche (21). The denomination “atrophie blanche” has 
long been used as both a descriptive term for ivory-white scars on the lower limbs, thought 
to be a result of chronic inflammation and microvascular occlusion and also as a diagnostic 
term in the case of LV. Notably, LV was initially described as a clinical manifestation of 
vasculitis, however, at present time, the main pathogenic mechanism driving it is considered 
to be vaso-occlusive processes, primarily deriving from intraluminal thrombosis (22). This 
notion is supported by the vast body of literature describing the positive therapeutic effects 
of fibrinolytic, antiplatelet therapy and anticoagulants in LV. The main acute complication 
due to these focal non-inflammatory thromboses is pain, which is later followed by atrophic 
scarring, ulceration, mononeuritis multiplex, hyperpigmentation and cutaneous 
hemosiderosis (23). During the disease evolution, a chronic but benign clinical course can 
be seen with intermittent recurrences and exacerbations. Livedo racemosa can often be seen, 
generally localized to the lower extremities. The possible involvement of the peripheral 
nervous system is thought to be the result of ischemia deriving from the deposition of fibrin 
or the formation of thrombi in the vasa nervorum (24). A number of publications have 
advocated the concept of LV being a cutaneous manifestation of certain prothrombotic 
processes, rather than a unique pathology in itself. Therefore, a broad number of diseases 
have been associated with LV through the disturbance of the Virchow’s triad, whether it be 
due to the disruption of the blood stasis in hyperviscosity syndromes, endothelial injury in 
systemic autoimmune diseases or hypercoagulability in thrombophilias (such as factor V 
Leiden mutation, protein C or S deficiency, elevated plasminogen activator inhibitor type 1) 
(23,25). Due to the heterogenous etiology and wide differential diagnosis of LV, 
histopathological examination is essential. The histopathological features of LV are 
characterized by occlusion of the superficial and/or middle dermal vessels by fibrin 
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deposition, intravascular thrombosis, segmental hyalinization and endothelial proliferation, 
all in the absence of vasculitis. Notably, such manifestations may also be apparent in the 
deep dermis. Deep biopsies are therefore necessary, as there are cases presenting with 
symptoms and histopathologic features suggestive of LV, but are actually the manifestations 
of CPAN (26). 
Cutaneous polyarteritis nodosa is a skin-limited necrotizing vasculitis, affecting the 
small and medium sized arteries in the dermal-subcutaneous junction, resulting in the 
aforementioned “atrophie blanche” skin symptoms (1). Notably, the classification schemes 
of polyarteritis nodosa (PAN) and other vasculitides have changed as our knowledge of their 
aetiopathogenesis evolved over time, also allowing for more specific treatment modalities 
in these disorders. The term necrotizing vasculitis is now regarded as a feature of a wide 
variety of diseases with different etiologies, which include classic PAN, microscopic 
polyangiitis (MPA), granulomatosis with polyangiitis (formerly known as Wegener 
granulomatosis) and eosinophilic granulomatosis with polyangiitis (formerly known as 
Churg-Strauss syndrome). It should be mentioned that distinguishing PAN from MPA 
proposed a major challenge and as a result, MPA has often been mentioned as microscopic 
polyarteritis, indicating it to be on the same spectrum as PAN.  
Subsequent studies have confirmed however, that MPA can be associated with 
ANCAs, thus establishing a distinction between the two. Furthermore, while PAN is not 
considered to be an inherited disease, certain mutations in specific genes may result in an 
identical clinical manifestation as PAN, such as the deficiency of ADA2 as part of a 
monogenic disease. Although CPAN predominantly affects the skin, extra-cutaneous 
symptoms may arise, such as fever, myalgias, arthralgias and neuropathy (mononeuropathy, 
mononeuropathy multiplex). While the first signs of systemic PAN may be the cutaneous 
lesions seen in CPAN, upon extensive clinical screening, multi-organ involvement is 
apparent, particularly in the kidneys, heart, GI tracts and the liver, hence the distinction 
between the two is essential (27). A comparative clinical study by Alibaz-Oner et al. also 
concluded that CPAN should be considered as an entirely separate entity from PAN, owing 
to its chronic relapsing and remitting benign clinical course and little to no mortality (28). 
While the etiopathogenesis of CPAN is still unclear, it is regarded as a disorder mediated by 
immune complexes, where direct immunofluorescence often shows C3 and IgM deposition 
(29). Intriguingly, a study by Kawakami et al. showed a 77.8% prevalence IgM antibodies 
targeting the phosphatidylserine-prothrombin complex in patient with CPAN, which would 
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then lead to the activation of the classical complement cascade through the production of 
anti-phosphatidylserine-prothrombin complex antibodies (30). On this note, the connection 
to prothrombotic processes have also been made, where warfarin therapy has been reported 
to be effective in the treatment of adult CPAN patients (31).  
To date, however, the conceptualization of thrombotic vs. inflammatory processes in 
LV and CPAN still continues to be perplexing (31,32). 
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2. AIMS 
Distinguishing a skin-limited variant of a vasculitis from its systemic form with a skin 
component before signs of internal involvement, grants an upper hand in therapeutic 
management, resulting in a lower risk of potential complications and mortality. To search 
for indicators in this matter, we examined adult patients with IgAV. IgAV is a small-vessel 
leukocytoclastic cutaneous vasculitis, often associated with kidney and GI manifestations. 
Although predictive factors for systemic involvement have been extensively studied in 
children, there is paucity in the literature regarding adults. NLR is an inflammatory marker, 
used to assess systemic inflammation in various diseases. 
I. Our aim was to evaluate whether NLR can predict and determine the presence and 
severity of the systemic involvement in adult IgAV patients, hence differentiating 
skin-limited IgAV from systemic IgAV with a skin component, while also providing 
prognostic practicality (Study I.) 
 
Though cutaneous biopsy remains an indispensable tool for diagnostic workup in the 
segregation of vasculitis and vasculopathy, clinical experience leaves us with controversy, 
without a definite etiopathological line distinguishing the two. LV and CPAN are rare 
cutaneous diseases of currently unknown etiologies. To date, the concept of thrombosis vs. 
inflammation in these entities continue to be ambiguous, with varying reports on the 
effectiveness of anticoagulant and immunosuppressant therapies.  
II. Our aim was to assess the presence of vasculopathy in adult patients with CPAN, 
with the added notion of LV and CPAN being constituents of a clinical evolution of 
focal vascular occlusion (Study II.) 
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3. MATERIAL AND METHODS 
3.1. Patients 
Study I. A retrospective review of adult patients diagnosed with IgAV between 
January 2004 and January 2016 was performed. In accordance with the study criteria used 
by Takeuchi et al. and Poterucha et al., patients needed to have palpable purpura consistent 
with the disease, skin biopsy specimen showing leukocytoclastic vasculitis on light 
microscopy and IgA deposition on direct immunofluorescence (33,34).  
Patients were excluded if they had an immunologic comorbidity, coexisting internal 
malignancy, hematological disorder, cryoglobulinemia or any chronic renal or GI diseases. 
Additionally, patients who experienced hematochezia, melena or hematemesis two days 
before or after blood sampling, were also excluded owing to the possibility of neutrophilia 
being the secondary effect of an acute hemorrhage. The flowchart of patient inclusion is 
depicted in Figure 1. 
Retrospective review of patients diagnosed with IgAV at our institution, 
between January 2004 and January 2016.  
• Palpable purpura 
• Leukocytoclastic vasculitis on light microscopy 
• IgA deposition on direct immunofluorescence 
82 patients identified 
Insufficient data (n = 15) 
Younger than 18 years (n = 4) 
Comorbidities: 
• Immunologic comorbidity (n = 3) 
• Coexisting internal malignancy (n = 1) 
• Hematological disorder (n = 2) 
• Chronic renal disease (n = 1) 
• Chronic gastrointestinal disease (n = 2) 
Presence of macroscopic bleeding two days before or after 
initial blood analysis (n = 2) 
Received treatment before initial blood sampling (n = 12) 
42 patients excluded 
40 patients met 
inclusion criteria 
Figure 1. Flowchart of adult IgA vasculitis patient inclusion 
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Study II. A retrospective study of eight patients with CPAN was conducted, who were 
treated at the Department of Dermatology and Allergology, University of Szeged, from 2010 
through 2018. The diagnosis of CPAN consisted of histopathological findings of necrotizing 
vasculitis of the small and medium-sized arteries at the dermal and subcutaneous junction, 
in addition to presence of clinical manifestations in accordance with CPAN, without any 
signs suggestive of systemic involvement (1). Cases that did not meet these criteria or lacked 
clinical information were not included in our report. We then compared our data with those 
found in the literature regarding the clinical, histopathological and prothrombotic laboratory 
parameters of LV, to determine whether prothrombotic processes may serve as a common 
ground in the etiopathology of CPAN and LV.  
Both retrospective studies were approved by the local ethics review committee. 
3.2. Data collection 
Study I. For adult patients with IgAV, we analyzed the medical records and registered 
the following: gender, age, duration of symptoms before blood sampling, clinical symptoms, 
results of laboratory testing and initial treatment. The laboratory test results included C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell count 
(WBC), neutrophil and lymphocyte counts, hematological parameters, urine and stool 
examinations. NLR was calculated based on the initial complete blood count test, by dividing 
the neutrophil count with the lymphocyte count. By reviewing the ambulatory records, we 
also registered any subsequent renal or GI symptoms following initial remission. Patients 
were followed from baseline visit until loss of follow-up or death. 
Study II. Regarding the medical records of CPAN cases, we recorded the age of onset 
of the disease, gender, duration of symptoms, clinical symptoms, notable medical history 
with concomitant medications, histopathologic features, initial treatment and laboratory 
data, which included the immunoserological and thrombophilia screening panel. To further 
assess the presence or absence of certain cutaneous symptoms of the disease, we revised an 
electronic photo documentation database, available at our institution, which prospectively 
enrolls patients. 
3.3. Assessment of GI and renal involvement in IgAV 
We defined GI involvement as clinical signs of hematochezia, melena or hematemesis, 
or a positive test result for fecal hemoglobin. Renal involvement was determined through 
hematuria (>5 red blood cells per high-power microscopic field in a centrifuged specimen; 
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in the absence of concurrent urinary tract infections, urolithiasis and anticoagulant therapy) 
or proteinuria (>150 mg/24h), or presence of predominant mesangial IgA deposition on the 
renal biopsy specimen. 
3.4. Statistical analysis 
Study I. The normality of distribution was analyzed using the Shapiro-Wilk test and 
parametric or non-parametric statistical tests were used accordingly. Quantitative variables 
are displayed as mean ± standard deviation (SD) or with median and interquartile range 
(IQR). Continuous variables were compared using one-way analysis of variance or Kruskal-
Wallis test for multiple groups and independent sample t-test or Mann-Whitney U test for 
dual groups. Categorical features are summarized with frequency count, percentage and were 
compared using Fisher’s exact test. The intercorrelations between parameters were examined 
using Spearman’s rank correlation coefficient test. A receiver operating characteristic (ROC) 
curve was performed to examine the prognostic utility of NLR and to identify the optimal 
cut-off value. Statistical analyses were performed using the Statistical Package for Social 
Science version 22 (SPSS Inc., Chicago, IL, USA) for Windows. All tests were two-tailed 
and P-values of less than 0.05 were considered statistically significant. 
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4. RESULTS 
4.1. Predictors of systemic involvement in adult IgAV patients (Study I.) 
4.1.1. Basic characteristics of the study sample 
Forty adult patients with IgAV who met the inclusion criteria were identified. The 
median age was 61 years (range 19-82 years). The cohort included 23 (57.5%) females and 
17 (42.5%) males. Half of the patients had clinical symptoms suggestive of GI and/or renal 
involvement, of which 6 (15%) had only renal, 3 (7.5%) had only GI and 11 (27.5%) had 
both renal and GI involvement. Because the presence or absence of arthritis and arthralgia 
was only recorded in 23 (57.5%) patients out of the enrolled 40 cases, we have not included 
this data in the statistical analysis. The median time between the appearance of cutaneous 
symptoms and initial blood analysis was 9.5 days (IQR 5-14 days). Patients received initial 
treatment after blood sampling and in all cases either corticosteroid monotherapy or a 
combination of corticosteroid and antibiotics were employed. Based on the severity of the 
subsequently developed renal and GI symptoms, therapies were altered accordingly at the 
discretion of the clinician. 
4.1.2. Clinical features 
As NLR represents an inflammatory response, we also included other routinely used 
inflammatory markers for comparison. Spearman correlation analysis indicated a significant 
correlation of NLR with CRP (ρ=0.482; p=0.002), ESR (ρ=0.37; p=0.019) and WBC 
(ρ=0.469; p=0.002), however no significant correlation was observed with the duration of 
symptoms before blood sampling (ρ=-0.269; p=0.094) or patient age (ρ=0.282; p=0.078), as 
depicted on Figure 2. To further exclude the possibility of an acute hemorrhage having an 
effect on NLR, we compared the hematological laboratory values of the enrolled patients 
based on their organ involvements, which did not indicate a significant difference between 
the groups (Figure 3).  
When stratifying patients based on their renal and GI manifestations and comparing 
the inflammatory laboratory parameters, there were no statistically significant differences, 
irrespective of which organ involvement the patients had (Figure 4). Intriguingly, CRP was 
quite low in those with only GI involvement, which may be due to the small number of 
patients in this group and their mild clinical manifestations of IgAV. These three patients 
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did not have extensive cutaneous symptoms and only displayed fecal hemoglobin positivity 
without any macroscopic bleeding of the GI tract. 
Because there were no statistically significant differences in the hematological and the 
inflammatory values following patient stratification with regards to their organ 
involvements, the enrolled cases were divided into two groups. 
 
Figure 2. Spearman correlation analysis between neutrophil-to-lymphocyte ratio, other 
inflammatory markers, duration of symptoms and patient age 
Figure 3. Hematological laboratory values of enrolled patients based on their organ involvements 
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While group 1 included patients who only had cutaneous symptoms, group 2 consisted 
of patients who developed GI and/or renal manifestations of IgAV, in addition to the 
cutaneous symptoms. The demographic and clinical characteristics of these two groups are 
detailed in Table 2. Of the registered inflammatory markers, CRP (p=0.002) and NLR 
(p<0.001) were significantly higher in group 2, whereas the other laboratory parameters, age, 
gender and the duration of symptoms were not statistically associated with systemic 
involvement (Figure 5).  
Six (30%) patients in group 2 displayed GI involvement with the presence of 
macroscopic bleeding, whereas eight (40%) only had fecal hemoglobin positivity without a 
clinically apparent hemorrhage. In cases where gross blood was observed, an endoscopic 
examination was performed, which showed IgAV compatible macroscopic image in all of 
these patients.  
Variable 
Group 1 
(n=20) 
Group 2 
(n=20) 
P-valuea 
Age; years, mean ± SD 56 ± 20 60 ± 16.3 0.493 
Gender, n (%)   0.056 
Female 13 (65) 6 (30)  
Male 7 (35) 14 (70)  
Duration of symptoms; days, median (IQR) 11 (7-15.3) 7.5 (4-12.5) 0.081 
Follow-up; months, median (IQR) 6.8 (3.5-24.9) 5.3 (2.1-19.1) NA 
End stage renal disease, n (%) 0 (0) 2 (10) NA 
Death, n (%) 0 (0) 1 (5) NA 
aFisher’s exact test was used to compare categorical variables. Student’s t-test was used to compare 
age and Mann-Whitney U test was used to compare the duration of symptoms and laboratory 
values. 
Table 2. Demographics and clinical features of patients with respect to their systemic involvement 
Figure 4. Inflammatory laboratory values of patients based on their organ involvements 
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With regards to renal symptoms, proteinuria was a frequent finding among those with 
a systemic involvement (n=15; 75%), however none of the patients developed nephrotic 
syndrome. In two patients, renal involvement progressed into end stage renal disease, 11 and 
14 days following initial blood analysis. A kidney biopsy was performed in both cases, 
which confirmed the association with IgAV. Additionally, these two individuals also 
developed severe GI bleeding, the former with intussusception and the latter with perforation 
as a secondary complication, both requiring surgical intervention. 
4.1.3. Receiver operating characteristic curves of NLR versus other inflammatory 
markers 
ROC curves of NLR and other inflammatory markers in relation to the systemic 
involvement are depicted in Figure 6. The area under the curve (AUC) for NLR, CRP, ESR 
and WBC was 0.892 (95% CI: 0.785-1; p<0.001), 0.779 (95% CI: 0.635-0.922; p=0.003), 
0.669 (95% CI: 0.498-0.839; p=0.068) and 0.637 (95% CI 0.462-0.813; p=0.089), 
respectively. Of the considered laboratory data, NLR provided the strongest diagnostic 
value, as indicated by the highest AUC value. The optimal cut-off value of NLR for 
predicting systemic involvement was 3.34, with a specificity of 95% and a sensitivity of 
85%. 
4.1.4. NLR and disease severity 
We further looked at the correlation of NLR and disease severity in patients with renal 
and/or GI involvement. For this, we have constructed a simple 7-point scoring system based 
on the clinical manifestations and course of the disease, observed among our enrolled cases.  
 
Figure 5. Inflammatory markers of patients with respect to their systemic involvement 
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Patients received 1 point for each of the following features: hematuria, proteinuria, 
renal impairment, fecal hemoglobin positivity, macroscopic bleeding from the GI tract, the 
necessity of intensive care / surgery / dialysis or blood transfusion and death. NLR was found 
to be significantly correlated with the disease severity score (ρ=0.51; p=0.022) (Figure 7). 
 
Figure 6. Receiver operating characteristic (ROC) curve of neutrophil-to-lymphocyte ratio versus 
other inflammatory markers 
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; NLR, neutrophil-to-lymphocyte 
ratio; WBC, white blood cell count. 
Figure 7. Correlation between neutrophil-to-lymphocyte ratio and disease severity in patients 
with systemic involvement 
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4.1.5. Assessing the applicability of NLR as a prognostic indicator in clinical practice 
We examined the applicability of NLR in clinical practice by randomly selecting three 
adult IgAV patients. The clinical presentations of these cases are depicted on Figure 8. The 
1st case is a 46-year-old female, who had relatively minor cutaneous symptoms, which 
developed two days before initial blood examination. Laboratory results showed a CRP level 
of 88.2 mg/L and an NLR of 6.7. As NLR was higher than the optimal cut-off value identified 
in our study, the patient was expected to develop systemic involvement, which she did in the 
form of proteinuria and colicky abdominal pain with fecal hemoglobin positivity. 
The 2nd case is a 54-year-old female, with a twenty-day history of skin lesions prior to 
initial laboratory examination, whose cutaneous symptoms were much worse than in the case 
of the 1st patient. Her CRP level was 55.6 mg/L and NLR showed a value of 2.27. In 
accordance with her NLR being below the cut-off value, she did not develop any clinically 
detectable symptoms of systemic involvement, despite having severe cutaneous symptoms. 
The 3rd case is a 70-year-old female patient, whose skin symptoms developed seven 
days before initial blood examination. Likewise, as in the previous case, she had a similar 
CRP of 53.1 mg/L, but a much higher NLR value (8.23). Four days later, the patient showed 
signs of severe GI bleeding with intussusception as a secondary complication, requiring 
surgical intervention. Eleven days later she also developed end stage renal disease. 
 
Figure 8. Photo documentation of the clinical presentations of adult patients with IgAV, taken 
within a day of initial blood examination 
Panel A: 1st case; Panel B: 2nd case; Panel C: 3rd case 
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4.2. Assessing the presence of vasculopathy in adult CPAN patients (Study II.) 
4.2.1. Clinical characteristics 
The clinical characteristics of the 8 patients are summarized in Table 3. The 5 male 
and 3 female (M:F ratio, 1.6) patients had a median age of 46 (range, 24–68 years) at 
diagnosis. The median duration of the relapsing symptoms before cutaneous biopsy 
sampling was 36 months (range, 2–240 months).  
The clinical manifestations consisted of purpura in 4 (50%), erythematous papules or 
plaques in 7 (87.5%), subcutaneous nodule in 1 (12.5%), livedo racemosa in 7 (87.5%), 
cutaneous ulcer in 7 (87.5%) and atrophie blanche in 7 (87.5%) cases. Without exception, 
the skin symptoms were always localized to the lower extremities, with notable predilection 
for the ankle regions. Notably, two of the patients (25%) also had peripheral neuropathy 
without motor deficit localized to the lower extremities, attributable to CPAN. Muscle-nerve 
biopsies in these instances were not performed. With regards to known comorbidities, 2 
(25%) patients had hypertension, of which one also had atrial fibrillation and was on 
apixaban treatment at the time of CPAN diagnosis. All cases were screened for antinuclear 
antibodies, ANCAs and complements, with negative results.  
4.2.2. Histological features 
In all cases, deep skin biopsies containing the subcutis were obtained. Each specimen 
displayed hyalinized dermal blood vessels, perivascular neutrophilic and lymphocytic 
infiltrate, leukocytoclasia and marked narrowing of the vessel lumens (Figure 9). Notable 
thrombosis was not apparent in most cases (87.5%), with only one specimen displaying 
extensive thrombosis in the papillary and deep dermis. Fibrinoid deposition in the papillary 
and deep dermal vessels was present in 7 (87.5%) patients. Direct immunofluorescent 
staining showed complement deposition in the vessel walls in 8 (100%) cases, with IgA in 
4 (50%) and IgM in 4 (50%) cases.  
4.2.3. Coagulation disorders 
Procoagulative conditions were found in 7 (87.5%) patients (Table 3). Elevated levels 
were detected of fibrinogen in 2 (25%), antithrombin III in 2 (25%), homocysteine in 1 
(12.5%), factor VIII in 3 (37.5%) cases. Protein S deficiency was detected in one (12.5%) 
patient and the lupus anticoagulant screening test was positive in 3 (37.5%) cases, without 
increased values in anti-cardiolipin or beta-2-glycoprotein antibodies.  
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Table 3. Clinical features and employed therapeutic modalities in patients with cutaneous 
polyarteritis nodosa. 
M, male; F, female; minus sign, absent; plus sign, present; LMWH, low molecular weight 
heparin. 
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4.2.4. Therapeutic regimen 
Initial therapies consisted of corticosteroids, however 3 (37.5%) patients required 
alteration in their immunosuppressants within a median of 4 months (range, 1.3-4.6 months; 
Table 3). Subsequently, only partial response was achieved long-term (median, 12 months; 
range, 7.2-58.1 months), thus, in consideration of the procoagulative parameters, warfarin 
therapy was initiated in all cases. All patients responded favourably to anticoagulation (case 
example illustrated on Figure 10). Three cases remained asymptomatic with warfarin 
monotherapy alone. 
Figure 9. Histopathological and clinical image of patient No 2. 
Panel A: Histopathology image showing segmental fibrinoid necrosis of a blood vessel, with 
marked perivascular neutrophilic and lymphocytic infiltrate, in addition to fibroelastic vessel 
wall thickening, causing narrowing of the lumen and focal vascular occlusion (hematoxylin 
and eosin staining); Panel B: Corresponding clinical image at the time of cutaneous biopsy 
sampling. 
Figure 10. Clinical images of patient No. 1 with cutaneous polyarteritis nodosa, depicting the 
improvement of skin symptoms following the addition of warfarin therapy to prednisolone. 
Panel A: Unresponsive cutaneous ulcerations following multiple immunosuppressant modalities. 
Skin symptoms after Panel B: 1 month, Panel C: 7 months, Panel D: 12 months, following the 
initiation of warfarin therapy. 
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4.3. Difficulty in the segregation of vasculitis and vasculopathy in clinical practice 
The proper distinction between vasculitis and vasculopathy is further challenged by 
the heterogenous pattern observed in each individual patient, comprised of environmental 
factors, genetics, comorbidities and their concurrent therapies as well as the current stage of 
the disease evolution. With a complex case detailed below, we wish to exemplify such a 
dilemma, from a clinician’s point of view.  
The present case describes a 49-year-old woman who had been diagnosed and treated 
with seropositive and anti-mutant-citrullinated vimentin antibody (MCV) positive 
rheumatoid arthritis (RA) for 13 years. Intriguingly, she also had intermitting cutaneous 
ulcerations on both legs in the previous 6 years, which were not characteristic for either LV 
nor CPAN and were not preceded with inflamed nodules. A skin biopsy was performed at 
the time, which showed leukocytoclastic vasculitis with IgM and C3 deposition, however, 
the patient never had purpuric lesions. Notably, perinuclear ANCA with indirect 
immunofluorescence and myeloperoxidase antibody with enzyme-linked immunosorbent 
assay were detected once, but no other symptoms specific of an ANCA-associated vasculitis 
were present. Antinuclear antibodies and anti-dsDNA were negative. In view of the high 
titer rheumatoid factor and anti-MCV-positivity, the presence of rheumatoid nodules, 
interstitial lung disease, pericarditis and mononeuritis, the cutaneous vasculitis was 
considered to be an extra-articular manifestation of RA. 
In 2009, thrombosis occurred in her upper right arm. Extensive clinical and laboratory 
examination with thrombophilia screening revealed heterozygote factor V Leiden mutation 
and the patient was put on acenocoumarol treatment. Retrospectively, this procoagulative 
state may have also played a major role in the development of the cutaneous ulcerations and 
their accompanying constant pain.  
She had previously been treated with varying doses of corticosteroid for 6 years, 
chloroquine, leflunomide, azathioprine and methotrexate; received cyclophosphamide 
(500mg) pulse therapy on 7 occasions, followed by adalimumab (40mg sc biweekly) for 15 
months. Tocilizumab (TCZ) is a humanized anti-human interleukin-6 (anti-IL-6) receptor 
antibody, which is used with success in the treatment of RA.  Anti-IL-6 biologic therapy was 
necessitated by the subsequent increase in her disease activity and TCZ was intravenously 
initiated in June 2013. Over the course of the next 19 months, the patient received 15 TCZ 
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infusions (8mg/kg), methotrexate (15mg/week) for 17 months and maintained a low dose of 
corticosteroid therapy (reduced from the initial 12mg/day to 4-2mg/day) for 14 months. 
During this time, her arthritis was inactive and the cutaneous ulcerations, due to her 
immunocomplex leukocytoclastic vasculitis, showed moderate improvements. 
She received her 16th TCZ treatment as a subcutaneous injection (162mg), in order to 
achieve a more consistent distribution of the medication. Three days following treatment, 
the patient experienced severe pain and burning sensation of the skin and was presented with 
multiple palpable purpuras with central necrotic areas mainly on the legs, buttocks and lower 
torso (Figure 11. A, B).  
Initial blood analysis showed minor C-reactive protein (7.2mg/l, normal value <5mg/l) 
elevation, increased D-dimer (15µg/ml, normal value <0.5µg/ml) levels and normal white 
blood cell count (6.5x109/l; neutrophils 63.9%). The patient had an INR value of 0.94, 
despite being on acenocoumarol treatment at the time. Liver and kidney functions were 
normal. Chest X-ray revealed bilateral interstitial reticular opacities. The patient did not have 
any clinical symptoms suggestive of pneumonia or abdominal pain and faecal occult blood 
testing was negative. Skin biopsy from a purpuric lesion revealed leukocytoclastic vasculitis 
with novel features of extensive intraluminal thrombosis and fibrinoid necrosis (Figure 11. 
C, D, E). Direct immunofluorescent staining of the specimen showed deposits of IgG in 
addition to IgM and C3.  
Because her cutaneous symptoms rapidly progressed and resembled lesions often seen 
in vasculopathies such as purpura fulminans, the patient was given two units of fresh frozen 
plasma on three occasions and received 125mg corticosteroid parentally, to which a marked 
improvement could be observed. Additionally, acenocoumarol was switched to enoxaparin. 
Subsequent laboratory results showed decrease in D-dimer (5.15µg/ml) values. Treatment 
proved to be efficient and the cutaneous lesions gradually ameliorated. As there were no 
newly administered medications, nor any recent infections, we concluded that the severe 
adverse skin symptoms were most likely induced by the most recent subcutaneous TCZ 
injection, thus further anti-IL-6 treatment was discontinued. Subsequently, the patient did 
not develop any purpuric lesions or thrombotic events throughout the following years.  
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Figure 11. Purpuric lesions in a patient with rheumatoid arthritis after three days of subcutaneous 
tocilizumab injection. 
Panel A, B: Multiple purpuric lesions with central necrotic areas on the thighs; Panel C: Light 
microscopic image showing leukocytoclastic vasculitis with erythrocyte extravasation; Panel D: 
Factor VIII immunohistochemical staining showing multiple thrombi in the blood vessel lumen; 
Panel E: PTAH staining of the specimen depicting multiple small blood vessels with signs of 
extensive fibrinoid necrosis. 
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5. DISCUSSION
Although IgAV is often a self-limiting and benign disease in children, severe 
complications may occur in adults, including renal impairment and serious GI bleeding, 
requiring intensive care or surgery (9,35). To date, no distinct differentiator can be employed 
in the stratification of skin-limited IgAV from a systemic IgAV with a skin component. As 
such, in accordance with current concepts, the two are considered to be on the same disease 
spectrum. A number of studies have been conducted with the aim to correlate various clinical 
features with systemic involvement in adults, such as direct immunofluorescence findings 
of skin biopsy specimens and skin lesion distribution, though the results are dissenting 
(33,34,36). Additionally, endoscopic features of GI lesions and histopathological findings of 
renal biopsies have also been studied, however these modalities can cause serious 
complications and may be contraindicated in certain cases (37,38).  Therefore, in order to 
gain more prognostic information, we examined the utility of a noninvasive and easily 
obtainable cost-effective laboratory parameter. To our knowledge this is the first biopsy-
proven case-control study to investigate the predictive value of NLR for systemic 
involvement in adult IgAV patients.  
Half of the patients included in Study I. developed renal and/or GI involvement, of 
which the majority concurrently had both organs affected. In  accordance with this finding, 
other studies have also noted high incidence of simultaneous renal and GI manifestations in 
adult IgAV (38,39). It should be mentioned however, that some researchers could not 
confirm this finding, which may be related to the varying criteria employed for defining 
systemic involvement (33,40). Male gender has also been previously described as a poor 
prognostic indicator for systemic involvement, however our results did not reach statistical 
significance (9,39). 
When stratifying patients based on their renal and GI involvement and comparing the 
registered laboratory results, there were no significant differences in the hematological and 
the inflammatory laboratory values, which implies that NLR and the other inflammatory 
markers are not organ specific prognostic indicators and their elevated values were not the 
secondary effect of an underlying severe bleeding. Consequently, the high NLR observed in 
our study, is therefore likely to be the result of an inflammatory response.  
Our results demonstrated that out of all the considered inflammatory parameters, NLR 
had the strongest prognostic value. The optimal cut-off point for predicting systemic 
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involvement was 3.34 with a specificity of 95% and a sensitivity of 85%. Additionally, we 
also found that pretreatment NLR values significantly correlated with the severity of the 
disease in patients who developed systemic involvement. It is important to note however, 
that when constructing the scoring system used to evaluate this correlation in our study, we 
only considered the presence or absence of certain clinical manifestations, rather than 
assessing the extent of renal or GI symptoms on a spectrum. In medical literature, the 
applicability of NLR in disease severity scoring is not new however, as it has been 
demonstrated viable for the measurement in the following scoring systems in patients with 
sepsis: Sequential Organ Failure Assessment, Simplified Acute Physiology Score III and 
Acute Physiology, Age, Chronic Health Evaluation (41,42). 
Progression to end stage renal disease was observed in two individuals. Compared to 
children, adult IgAV patients are more likely to present with a delayed renal involvement, 
often requiring close monitoring and diligent testing for even up to 6 months following the 
onset of IgAV, despite favorable initial laboratory results (43). While delayed renal 
involvement was not observed in any of our cases, it should be noted that 20 patients (10 
individuals from group 1 and 10 individuals from group 2) did not have a follow-up time 
period of at least 6 months. Although one of the patients with a lower NLR than the cut-off 
value identified in our study developed renal manifestations of IgAV (in the form of 
microscopic hematuria and proteinuria) during his admission, he remained asymptomatic 
throughout the follow-up time period (9 years).  
More than a third of our patients had GI involvement, which is in accordance with 
previous reports (9,10). In most cases, the symptoms consisted of colicky abdominal pain 
with fecal hemoglobin positivity, however some patients developed macroscopic bleeding. 
Severe complications, such as intussusception and perforation were also observed in two 
cases, the latter resulting in a fatal outcome. None of the patients in our cohort with a lower 
NLR value than 3.34 displayed any clinical signs suggestive of GI involvement, during their 
admission and follow-up, which further highlights the prognostic value of NLR. Although a 
recent study demonstrated the applicability of this ratio with regards to GI bleeding in adult 
patients with cutaneous vasculitis, the employed criteria for the diagnosis of IgAV did not 
include skin histopathology examination (44). In consideration of the probable clinical 
overlap between hypersensitivity vasculitis and IgAV, differentiating between these two 
entities is imperative when assessing and predicting renal or GI involvement (45). 
Consequently, the clinical significance of the presence or absence of IgA deposition found 
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by direct immunofluorescence of the cutaneous biopsy specimen should not be overlooked, 
as it enhances the diagnostic specificity (4,46,47). 
The significance of our findings is limited by the retrospective nature of Study I. and 
its single-center sample size. Nevertheless, as our selection was based on both clinical and 
histopathological findings, with the exclusion of patients with other background diseases, 
we believe our data represent accurate observations. Larger prospective multi-center studies 
are required to validate our findings and to establish a generally acceptable cut-off value of 
this ratio. The routine testing for qualitative blood count in clinical practice at minimal cost 
and little-to-no risk to the patient makes NLR a promising measurement for systemic 
inflammation. Whether the viability of this biomarker permits the development of 
prospective therapeutic studies, remains to be determined. Nonetheless, there seems to be 
reasonable potential for this marker as a tool for clinical risk stratification at the time of 
IgAV diagnosis, thus also allowing for a more patient-specific therapeutic intervention.  
On the matter of the vasculitis and vasculopathy conundrum, we examined the clinical 
features of a single-organ vasculitis of the skin, focusing on the presence of procoagulative 
components of the disease.   
Presently, CPAN is considered to be a necrotizing vasculitis and although its etiology 
is not fully elucidated, current concepts advocate that it is mediated by immune complex 
deposition (29). Likewise, the pathogenesis of LV also lingers on uncertain grounds, though, 
the interpretation of non-inflammatory thrombosis of the dermal vessels remains to be 
widely accepted (25). 
Contrariwise, reports of LV and CPAN not responding to the conventional treatments, 
leave us with controversy regarding the aforementioned concepts (31,48). 
Additionally, despite the presumed difference in their underlying pathomechanisms, 
these two entities share notable clinical similarities not only in their cutaneous 
manifestations but also in their recurrent and usually non-progressive clinical courses, 
implicating a link amongst their pathophysiological mosaics.  
In Study II. the cutaneous manifestations of CPAN were compatible with LV in all 
cases, with pain being a constant subjective symptom. Intriguingly, despite the vast majority 
of the literature highlighting the presence of subcutaneous nodules, only one patient 
displayed such lesions upon presentation. Contrarily, the pathologic form of livedo 
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reticularis, also regarded as livedo racemosa, was present in all but one of the cases. While 
livedo reticularis can develop due to vessel wall pathology (when medium-sized arterioles 
of the dermal-subcutaneous layer are affected), it may also be a sign of intraluminal 
pathology, either owing to a slowed intravascular blood flow or complete obstruction of the 
vessel lumen. As a result, the cutaneous zone of the venous predominance is affected, 
causing the dilation of the cutaneous venules and accumulation of deoxygenated blood in 
the venous plexus, leading to the clinical presentation of the characteristic net-like pattern 
(49). Obstruction can result from either an emboli (e.g. cholesterol emboli) or thrombosis, 
thus linking it to hypercoagulative states, such as antiphospholipid syndrome, protein C, S 
or antithrombin III deficiency. In LV, a combination of both vessel wall pathology and 
intraluminal obstruction is postulated which is also in line with CPAN. Atrophie blanche 
was a prominent feature in the majority of cases. For an extended period of time, this term 
was used as a diagnostic descriptor for livedoid vasculitis, which was later revised as LV, 
denoting the presence of blood vessel lumen obstruction, seen as segmental hyaline 
degeneration of the vessel wall, endothelial proliferation and deposition of fibrin in the 
lumen (50,51). Additional manifestations of the series included peripheral neuropathy in two 
of our patients, which has also been described in LV, thought to be the result of the 
thrombotic processes affecting the vasa nervorum (24,52). No evidence of autoimmune 
abnormalities were detected in our series, thus excluding other forms of vasculitis or 
rheumatologic diseases.  
Histological features of our study sample displayed segmental hyalinizing vasculitis, 
with intravascular deposition of fibrin and secondary changes deriving from vascular 
occlusion. Perivascular lymphocytic infiltrate, in addition to neutrophils, was a prominent 
feature in our cases, which is also often seen in LV (53). Albeit extensive intraluminal 
thrombosis, characteristic of LV, could only be seen in one of our cases, it is commonly 
described in CPAN alike (54). Whilst LV initially appears with a histopathologic picture 
showing fibrin thrombi without evidence of inflammation, it is later presented as hyalinized 
fibrin rings with lymphocytic infiltrate, signs of vasculitis and erythrocyte extravasation, 
accompanied by neutrophilic infiltrate and immunoglobulin deposition (21,23,55). As the 
duration of symptoms before biopsy sampling was protracted in our series, it further 
underscores the concept of disease evolution as deciphering primary and secondary 
histopathologic features remain to be challenging. Additionally, while superficial skin 
histopathology may show vessel occlusion identical to LV, they are secondary changes to 
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the inflamed vessels in the deep dermis, thus, superficial biopsies can be misleading in 
CPAN, which may also explain the discrepancy in the literature (56). This further 
underscores the importance of deep cutaneous biopsies and may also accentuate the 
necessity of repeated excisional biopsies to reveal the true underlying pathology. Llamas-
Velasco et al. further emphasizes the interrelation between the two by demonstrating LV and 
CPAN coexisting within the same skin biopsy specimen (53). 
Similar to a hypercoagulable state seen in LV, we found coagulopathies in the majority 
(87.5%) of our patients, giving a considerable role for anticoagulant therapy in CPAN as 
well. While immunosuppressives are the mainstay, long-term management of our patients 
necessitated the introduction of anticoagulative treatment, with good therapeutic response 
(31,32). Although cutaneous biopsy provides essential morphological insights, it is also 
important to consider the clinical experience and therapeutic responses, hence, we believe a 
considerable role should be given to the vasculopathic aspects of CPAN, in addition to 
vasculitis, which may serve as a common ground for widening our scope of the vasculopathy 
vs. vasculitis question. 
As a limitation of this retrospective study on such a rare disease, we acknowledge the 
small sample population, however, in consideration of the continued controversy regarding 
thrombosis vs. inflammation, our endeavour was to propose a new approach to the matter in 
question by affiliating LV with CPAN in the context of constituents of a clinical evolution: 
a changing face of focal vascular occlusion.  
Lastly, the accentuation of thrombosis and inflammation going hand-in-hand must be 
noted as more evidence comes to light regarding the intricate connection between the innate 
immunity and the coagulative cascade, a pathomechanism which has been termed 
immunothrombosis (57). Immune-mediated thrombosis is thought to be an early stepping 
stone in the evolution of the immune system, where the innate immune cells developed 
prothrombotic pathways as a form of protection against pathogens in the vasculature by 
thrombi formation to capture and limit the spreading of pathogens (58). The basic principles 
behind this response are the activation of monocytes, neutrophils and their interaction with 
the coagulation cascade. These innate immune cell specific pathways serve as potentiators 
for thrombosis, which are activated by certain stimuli, such as the presence of pathogen-
associated molecular patterns or damage-associated molecular patterns. When activated, 
monocytes are able to release tissue factor expressing microparticles, which then activate the 
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extrinsic coagulation pathway, while neutrophils are capable of releasing neutrophil 
extracellular traps (NETs), which are comprised of DNA matrix, harboring histones, 
nucleosomes and neutrophil elastase (Figure 12) (59,60). NETs are considered to be crucial 
structural factors in the formation of immune-elicited thrombi, as they promote the intrinsic 
coagulation pathway by activating factor XII, as well as directly initiating fibrin formation 
(57). Previous studies have also demonstrated that these processes occur in 
autoinflammatory disorders, in the absence of microbial pathogens, such as in ACNA-
associated vasculitides (61–63). Owing to these mechanisms, increased prevalence of 
thrombosis has been observed in several other autoimmune diseases (64). 
 
The described complex case of RA with TCZ-associated adverse reaction poses a 
number of questions regarding the possible underlying pathomechanisms. On the matter of 
an inflammation driven process, most biologic-agent-induced vasculitis case reports are 
associated with antitumor necrosis factor-α (anti-TNF-α) therapies. Although their 
pathophysiology is still poorly understood, probable mechanisms have been proposed such 
as the formation of anti-TNF-α-TNF-α immunocomplex which results in type III 
hypersensitivity (65). It may be plausible that TCZ can induce vasculitis through a similar 
Figure 12. The basic principles of immunothrombosis 
DAMP, damage-associated molecular patterns; FXIIa, activated factor XII; NETs, neutrophil 
extracellular traps; MPO, myeloperoxidase; PAMP, pathogen-associated molecular patterns; 
PRR, pattern-recognition receptor; Thr, thrombocyte; vWF, von Willebrand factor 
Reproduced from reference (57). 
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process, by binding to soluble IL-6 receptors and creating immune deposits in the 
vasculature, which process may be supported by the presence of IgG deposition found in the 
direct immunofluorescence specimen of the present case, considering that TCZ is a 
humanized IgG1 class monoclonal antibody (66). 
On the other hand, it may also be reasonable to consider that TCZ was not part of the 
immunocomplex but was perhaps involved in an indirect way. Compared to anti-TNF-α 
therapies, only a few cases with TCZ-induced immune disorders have been described, which 
might also suggest a lower immunogenicity or a prerequisite of specific factors which then 
promote susceptibility (67,68). It is of interest that the presented skin aberrations manifested 
so profoundly. In our patient, the main engrossing histopathological findings were the 
significant amounts of thrombi in the cutaneous vasculature, seen in vasculopathies. In light 
of the markedly elevated D-dimer, a thrombogenic effect was responsible for the severity of 
this reaction. IL-6 plays an important role in the pathogenesis of autoimmunity and also 
facilitates blood coagulation through various pathways (69,70). It is possible that 
administration of TCZ could have increased serum IL-6 levels due to the antibodies binding 
to IL-6 receptors leading to thrombosis in the cutaneous microvasculature, thus causing the 
observed necrotic lesions on the skin. The patient’s activated protein C resistance might have 
also played a pivotal role by not only lack of its anticoagulatory functions but through its 
cell adhesion and cytokine modulation effects, resulting in the up-regulation of IL-6 in 
endothelial cells (71). Previous studies have also reported an increase in serum IL-6 levels 
following TCZ administration, noting major differences between individual patients (72). 
The increase in serum IL-6 levels or a TCZ-induced immunogen response may have been 
the tipping point in precipitating this adverse effect by unbalancing the equilibrium between 
the coagulatory and anticoagulatory system, resulting in the initiation of immunothrombosis 
in the cutaneous microvasculature. This process may have also accounted for the significant 
effectiveness of fresh frozen plasma infusions and the changes in serum D-dimer levels 
throughout the treatment.  
Additionally, it has also been previously shown that IL-6 down-regulates cytochrome 
P450 (CYP) isozymes (73). As acenocoumarol is metabolized by CYP2C9, blockage of IL-
6 signaling may therefore result in an altered bioavailability of the medication (74). Notably, 
no clinical studies investigating the interaction between TCZ and anticoagulants are 
available, however TCZ-associated thrombotic events have been reported in the medical 
36 
 
literature (75,76). The concurrent subcutaneous administration of TCZ could have also 
caused an ineffectiveness of the acenocoumarol therapy, resulting in a procoagulative state, 
owing to the patient’s factor V Leiden heterozygosity. A clinical study by Burmester et al. 
has also shown that the mean TCZ concentrations in patients receiving subcutaneous 
injections were twice as high compared to those receiving it intravenously, which would 
further support this hypothesis and explain why this adverse event did not occur in our 
patient while she was receiving intravenous TCZ therapy (77). 
In closing perspective, this single case could further raise many questions whether the 
event was an inflammation or thrombosis driven process, also highlighting the additional 
potential factors of consideration, owing to the clinical complexity deriving from the 
patient’s comorbidities and concurrent medications. As previously mentioned, the clinical 
experience should compose a crucial factor in addition to the histopathological examination 
throughout the frameworks of the diagnostic workup. The significance of recognizing the 
presence of both vasculitis and vasculopathy is underlined by the good therapeutic effect of 
the employed treatment modalities in our described case(s). Of point, even in situations 
where the dominant feature of the clinical presentation is inflammation, procoagulative 
aspects need to be taken into consideration as part of the thrombotic continuum enveloping 
both hemostasis and immunothrombosis. Subsequent future work will be needed to expand 
on the dysregulations of the intravascular innate immune responses in specific diseases and 
to identify underlying triggers for immunothrombosis. Discerning such facilitators will not 
only expand our understanding of this pathogenesis but will consequently enable the 
establishment of new diagnostic and therapeutic modalities.  
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6. CONCLUSIONS
I. Our results suggest that NLR is a potential prognostic marker for systemic involvement
in adult IgAV and can be used to identify patients at risk of developing extracutaneous
manifestations.
II. We also found that increased pretreatment NLR correlated with the severity of the
systemic involvement, which may aid in the stratification of patients into risk groups.
III. In addition to vasculitis, the vasculopathic aspects of CPAN should be recognized as
well, giving a considerable role for anticoagulative therapy. Though histopathological
assessment regards CPAN as a vasculitis, clinical experience suggests a more complex
underlying pathomechanism, where vasculitis and vasculopathy may be intertwined
throughout a dynamic clinical evolution.
IV. Further prospective studies on mapping the disease stages of focal vascular occlusion,
with CPAN in its focus, should broaden the horizon and help us elucidate the full scope
of the underlying pathomechanism.
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Abstract
Background IgA vasculitis (IgAV) is a small-vessel leucocytoclastic cutaneous vasculitis, often associated with kidney
and gastrointestinal (GI) manifestations. Although predictive factors for systemic involvement have been extensively
studied in children, there is paucity in the literature regarding adult patients. Neutrophil-to-lymphocyte ratio (NLR) is an
inflammatory marker, used to assess systemic inflammation in various diseases.
Objective We sought to evaluate whether NLR can be used for predicting renal and GI involvement in adult IgA vasculi-
tis patients.
Methods This was a retrospective review of adult patients who were diagnosed with IgAV at our institution between
2004 and 2016.
Results A total of 40 patients met our inclusion criteria. Half of the enrolled patients had clinical symptoms suggestive
of systemic involvement, of which 6 (15%) had only renal, 3 (7.5%) had only GI and 11 (27.5%) had both renal and GI
involvement. Pretreatment NLR was significantly associated with renal and/or GI manifestations of the disease
(P < 0.001). The optimal cut-off value of NLR, for predicting systemic involvement was 3.34, with a specificity of 95%
and a sensitivity of 85%. In addition, pretreatment NLR was also found to be significantly correlated with the severity of
the systemic manifestations of IgAV (P = 0.022).
Conclusion This study suggests that NLR is a potential indicator for prognosticating systemic involvement in adult
IgAV.
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Introduction
Immunoglobulin A vasculitis (IgAV), formerly known as
Henoch-Sch€onlein purpura, is an immune complex-mediated
small-vessel leucocytoclastic cutaneous vasculitis, characterized
by palpable purpura, arthralgia or arthritis, gastrointestinal (GI)
and renal involvement.1 It is often regarded as a disease of child-
hood, but contrary to popular belief, it is not uncommon in
adults.2 Although it is considered to be the same entity, the clini-
cal manifestations and disease course differ greatly in these two
age groups. Previous studies have demonstrated that unlike in
children, adult patients develop systemic involvement more fre-
quently, with a high risk of severe GI bleeding and chronic kid-
ney disease.3,4 This highlights the importance and the need of
prognostic markers that can help identify IgAV patients who are
at risk of developing unfavourable extracutaneous manifesta-
tions. While predictive factors have been extensively studied in
children, there are limited data on adults.5–7
Blood neutrophil-to-lymphocyte ratio (NLR) is an inexpen-
sive and easily obtainable laboratory marker for quantifying sys-
temic inflammation, which has been used to predict clinical
outcomes in patients with various internal malignancies, cardio-
vascular disease and liver cirrhosis.8–12 As this ratio integrates
information on two immune pathways, it may provide a predic-
tive ability that outweighs other inflammatory parameters. The
aim of this study was to evaluate the utility of this ratio in pre-
dicting renal and GI involvement in adult IgAV patients.
Patients and methods
Patients
A retrospective review of adult patients diagnosed with IgAV
between January 2004 and January 2016 was performed. In
accordance with the study criteria used by Takeuchi et al.13 and
Poterucha et al.,14 patients needed to have palpable purpura
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consistent with the disease, skin biopsy specimen showing leuco-
cytoclastic vasculitis on light microscopy and IgA deposition on
direct immunofluorescence.
Patients were excluded if they had an immunologic comor-
bidity, coexisting internal malignancy, haematological disorder,
cryoglobulinemia or any chronic renal or GI diseases. Addition-
ally, patients who experienced hematochezia, melena or
hematemesis 2 days before or after blood sampling, were also
excluded owing to the possibility of neutrophilia being the sec-
ondary effect of an acute haemorrhage.
The study was approved by the local ethics review committee.
Data collection
We analyzed the medical records and registered the following:
gender, age, duration of symptoms before blood sampling, clini-
cal symptoms, results of laboratory testing and initial treatment.
The laboratory test results included C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), white blood cell count
(WBC), neutrophil and lymphocyte counts, haematological
parameters, urine and stool examinations. NLR was calculated
based on the initial complete blood count test, by dividing the
neutrophil count with the lymphocyte count. By reviewing the
ambulatory records, we also registered any subsequent renal or
GI symptoms following initial remission. Patients were followed
from baseline visit until loss of follow-up or death.
Assessment of gastrointestinal and renal involvement
We defined GI involvement as clinical signs of hematochezia,
melena or hematemesis; or a positive test result for faecal hae-
moglobin. Renal involvement was determined through haema-
turia (>5 red blood cells per high-power microscopic field in a
centrifuged specimen; in the absence of concurrent urinary tract
infections, urolithiasis and anticoagulant therapy) or proteinuria
(>150 mg/24 h), or presence of predominant mesangial IgA
deposition on the renal biopsy specimen.
Statistical analysis
The normality of distribution was analyzed using the Shapiro–
Wilk test and parametric or non-parametric statistical tests
were used accordingly. Quantitative variables are displayed as
mean  standard deviation (SD) or with median and
interquartile range (IQR). Continuous variables were compared
using one-way analysis of variance or Kruskal–Wallis test for
multiple groups and independent sample t-test or Mann–Whit-
ney U test for dual groups. Categorical features are summarized
with frequency count, percentage and were compared using
Fisher’s exact test. The intercorrelations between parameters
were examined using Spearman’s rank correlation coefficient
test. A receiver operating characteristic (ROC) curve was per-
formed to examine the prognostic utility of NLR and to iden-
tify the optimal cut-off value. Statistical analyses were
performed using the Statistical Package for Social Science
version 22 (SPSS Inc., Chicago, IL, USA) for Windows. All tests
were two-tailed and P-values of less than 0.05 were considered
statistically significant.
Results
Basic characteristics of the study sample
Forty adult patients with IgAV who met the inclusion criteria
were identified. The median age was 61 years (range 19–
82 years). The cohort included 23 (57.5%) females and 17
(42.5%) males. Half of the patients had clinical symptoms sug-
gestive of GI and/or renal involvement, of which six (15%) had
only renal, three (7.5%) had only GI and 11 (27.5%) had both
renal and GI involvement. Because the presence or absence of
arthritis and arthralgia was only recorded in 23 (57.5%) patients
of the enrolled 40 cases, we have not included this data in the
statistical analysis. The median time between the appearance of
cutaneous symptoms and initial blood analysis was 9.5 days
(IQR 5–14 days). Patients received initial treatment after blood
sampling and in all cases either corticosteroid monotherapy or a
combination of corticosteroid and antibiotics were employed.
Based on the severity of the subsequently developed renal and GI
symptoms, therapies were altered accordingly at the discretion
of the clinician.
Clinical features
As NLR represents an inflammatory response, we also included
other routinely used inflammatory markers for comparison.
Spearman correlation analysis indicated a significant correlation
of NLR with CRP (q = 0.482; P = 0.002), ESR (q = 0.37;
P = 0.019) and WBC (q = 0.469; P = 0.002); however, no sig-
nificant correlation was observed with the duration of symptoms
before blood sampling (q = 0.269; P = 0.094) or patient age
(q = 0.282; P = 0.078). To further exclude the possibility of an
acute haemorrhage having an effect on NLR, we compared the
haematological laboratory values of the enrolled patients based
on their organ involvements, which did not indicate a significant
difference between the groups (Table 1).
When stratifying patients based on their renal and GI mani-
festations and comparing the inflammatory laboratory parame-
ters, there were no statistically significant differences,
irrespective of which organ involvement the patients had
(Table 2). Intriguingly, CRP was quite low in those with only GI
involvement, which may be due to the small number of patients
in this group and their mild clinical manifestations of IgAV.
These three patients did not have extensive cutaneous symptoms
and only displayed faecal haemoglobin positivity without any
macroscopic bleeding of the GI tract.
Because there were no statistically significant differences in
the haematological and the inflammatory values following
patient stratification with regard to their organ involvements,
the enrolled cases were divided into two groups.
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While group 1 included patients who only had cutaneous
symptoms, group 2 consisted of patients who developed GI
and/or renal manifestations of IgAV, in addition to the cuta-
neous symptoms. The demographic and clinical characteristics
of these two groups are detailed in Table 3. Of the registered
inflammatory markers, CRP (P = 0.002) and NLR
(P < 0.001) were significantly higher in group 2, whereas the
other laboratory parameters, age, gender and the duration of
symptoms were not statistically associated with systemic
involvement.
Six (30%) patients in group 2 displayed GI involvement with
the presence of macroscopic bleeding, whereas eight (40%) only
had faecal haemoglobin positivity without a clinically apparent
haemorrhage. In cases where gross blood was observed, an endo-
scopic examination was performed, which showed IgAV com-
patible macroscopic image in all of these patients.
With regard to renal symptoms, proteinuria was a fre-
quent finding among those with a systemic involvement
(n = 15; 75%); however, none of the patients developed
nephrotic syndrome. In two patients, renal involvement pro-
gressed into end-stage renal disease, 11 and 14 days follow-
ing initial blood analysis. A kidney biopsy was performed in
both cases, which confirmed the association with IgAV.
Additionally, these two individuals also developed severe GI
bleeding, the former with intussusception and the latter with
perforation as a secondary complication, both requiring
surgical intervention.
Receiver operating characteristic curves of NLR versus
other inflammatory markers
ROC curves of NLR and other inflammatory markers in relation
to the systemic involvement are depicted in Fig. 1. The area
under the curve (AUC) for NLR, CRP, ESR and WBC was 0.892
(95% CI: 0.785–1; P < 0.001), 0.779 (95% CI: 0.635–0.922;
P = 0.003), 0.669 (95% CI: 0.498–0.839; P = 0.068) and 0.637
(95% CI 0.462–0.813; P = 0.089), respectively. Of the considered
laboratory data, NLR provided the strongest diagnostic value, as
indicated by the highest AUC value. The optimal cut-off value of
Table 2 Inflammatory laboratory values of patients with systemic manifestations based on their organ involvements
Variable Renal involvement
(n = 6)
GI involvement
(n = 3)
Renal and GI involvement
(n = 11)
P-value*
CRP (mg/L), mean  SD 85.3  48.2 13  12.3 105  93.3 0.051
ESR (mm/h), mean  SD 59.2  44.7 24.3  20.8 50  28.8 0.334
WBC (9109/L), mean  SD 9.3  2.5 11  2.9 12.1  5.4 0.635
NLR, mean  SD 4.2  1.7 5.4  1.5 7.4  3.4 0.057
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GI, gastrointestinal; NLR, neutrophil-to-lymphocyte rate; WBC, white blood cell count.
*Continuous variables were compared using the Kruskal–Wallis test.
Table 1 Haematological laboratory values of enrolled patients based on their organ involvements
Variable Renal involvement
(n = 6)
GI involvement
(n = 3)
Renal and GI
involvement (n = 11)
No renal or GI
involvement (n = 20)
P-value*
Haemoglobin (g/dL), mean  SD 128.5  26.8 144.7  19.6 127.6  20.3 133  19 0.483
Haematocrit (L/L), mean  SD 0.38  0.1 0.42  0.1 0.38  0.1 0.39  0.1 0.628
Erythrocyte count (91012/L), mean  SD 4.39  0.9 4.74  0.49 4.26  0.49 4.45  0.53 0.591
Platelet count (9109/L), mean  SD 278.5  61.9 240.7  20.9 306.7  132.8 282.1  71.9 0.558
*Continuous variables were compared using the Kruskal–Wallis test.
Table 3 Demographics and clinical findings of patients with
respect to their systemic involvement
Variable Group 1
(n = 20)
Group 2
(n = 20)
P-value*
Age; years,
mean  SD
56  20 60  16.3 0.493
Gender, n (%) 0.056
Female 13 (65) 6 (30) NA
Male 7 (35) 14 (70) NA
Duration of symptoms;
days, median (IQR)
11 (7–15.3) 7.5 (4–12.5) 0.081
CRP (mg/L),
median (IQR)
13.1 (7.3–48.9) 68.2 (25.7–124.3) 0.002
ESR (mm/h),
median (IQR)
22 (10–34.3) 43.5 (21.5–79.3) 0.068
WBC (9109/L),
median (IQR)
8.2 (6.6–12) 10.9 (8.1–12.3) 0.142
NLR, median (IQR) 2.6 (1.6–3) 5.9 (4.3–7.1) <0.001
Follow-up; months,
median (IQR)
6.8 (3.5–24.9) 5.3 (2.1–19.1) NA
End–stage renal
disease, n (%)
0 (0) 2 (10) NA
Death, n (%) 0 (0) 1 (5) NA
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR,
interquartile range; NLR, neutrophil-to-lymphocyte rate; WBC, white blood
cell count.
*Fisher’s exact test was used to compare categorical variables. Student’s t-
test was used to compare age and Mann–Whitney U test was used to com-
pare the duration of symptoms and laboratory values.
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NLR for predicting systemic involvement was 3.34, with a speci-
ficity of 95% and a sensitivity of 85%.
NLR and disease severity
We further looked at the correlation of NLR and disease severity
in patients with renal and/or GI involvement. For this, we have
constructed a simple 7-point scoring system based on the clinical
manifestations and course of the disease, observed among our
enrolled cases. Patients received 1 point for each of the following
features: haematuria, proteinuria, renal impairment, faecal hae-
moglobin positivity, macroscopic bleeding from the GI tract, the
necessity of intensive care/surgery/dialysis or blood transfusion
and death. NLR was found to be significantly correlated with the
disease severity score (q = 0.51; P = 0.022) (Fig. 2).
Discussion
Although IgAV is often a self-limiting and benign disease in chil-
dren, severe complications may occur in adults, including renal
impairment and serious GI bleeding requiring intensive care or
surgery.3,15 A number of studies have been conducted with the
aim to correlate various clinical features with systemic involve-
ment in adults, such as direct immunofluorescence findings of
skin biopsy specimens and skin lesion distribution, although the
results are dissenting.13,14,16 Additionally, endoscopic features of
GI lesions and histopathological findings of renal biopsies have
also been studied; however, these modalities can cause serious
complications and may be contraindicated in certain cases.4,17
Therefore, to gain more prognostic information, we examined
the utility of a noninvasive and easily obtainable cost-effective
laboratory parameter. To our knowledge, this is the first biopsy-
proven case–control study to investigate the predictive value of
NLR for systemic involvement in adult IgAV patients.
Half of the patients included in our study developed renal
and/or GI involvement, of which the majority concurrently had
both organs affected. In accordance with this finding, other
studies have also noted high incidence of simultaneous renal and
GI manifestations in adult IgAV.4,18 It should be mentioned,
however, that some researchers could not confirm this finding,
which may be related to the varying criteria employed for defin-
ing systemic involvement.13,19 Male gender has also been previ-
ously described as a poor prognostic indicator for systemic
involvement; however, our results did not reach statistical signif-
icance.3,18
When stratifying patients based on their renal and GI involve-
ment and comparing the registered laboratory results, there were
no significant differences in the haematological and the inflam-
matory laboratory values, which implies that NLR and the other
inflammatory markers are not organ-specific prognostic indica-
tors and their elevated values were not the secondary effect of a
severe bleeding. Consequently, the high NLR observed in our
study is, therefore, likely to be the result of an inflammatory
response.
Our results demonstrated that of all the considered inflamma-
tory parameters, NLR had the strongest diagnostic value. The
optimal cut-off point for predicting systemic involvement was
3.34 with a specificity of 95% and a sensitivity of 85%. Addition-
ally, we also found that pretreatment NLR values significantly
correlated with the severity of the disease in patients who devel-
oped systemic involvement. It is important to note, however,
that when constructing the scoring system used to evaluate this
correlation in our study, we only considered the presence or
absence of certain clinical manifestations, rather than assessing
the extent of renal or GI symptoms on a spectrum.
Progression to end-stage renal disease was observed in two
individuals. Compared to children, adult IgAV patients are more
likely to present with a delayed renal involvement, often requir-
ing close monitoring and diligent testing for even up to
6 months following the onset of IgAV, despite favourable initial
laboratory results.20 While delayed renal involvement was not
observed in any of our cases, it should be noted that 20 patients
(10 individuals from group 1 and 10 individuals from group 2)
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did not have a follow-up time period of at least 6 months.
Although one of the patients with a lower NLR than the cut-off
value identified in our study developed renal manifestations of
IgAV (microscopic haematuria and proteinuria) during his
admission, he remained asymptomatic throughout the follow-
up time period (9 years).
More than a third of our patients had GI involvement, which
is in accordance with previous reports.3,4 In most cases, the
symptoms consisted of colicky abdominal pain with faecal hae-
moglobin positivity; however, some patients developed macro-
scopic bleeding. Severe complications, such as intussusception
and perforation were also observed in two cases, the latter result-
ing in a fatal outcome. None of the patients in our cohort with a
lower NLR value than 3.34 displayed any clinical signs suggestive
of GI involvement, during their admission and follow-up, which
further highlights the prognostic value of NLR. Although a
recent study demonstrated the applicability of this ratio with
regard to GI bleeding in adult patients with cutaneous vasculitis,
the employed criteria for the diagnosis of IgAV did not include
skin histopathology examination.21 In consideration of the prob-
able clinical overlap between hypersensitivity vasculitis and
IgAV, differentiating between these two entities is imperative
when assessing and predicting renal or GI involvement.22 Conse-
quently, the clinical significance of the presence or absence of
IgA deposition found by direct immunofluorescence of the cuta-
neous biopsy specimen should not be overlooked, as it enhances
the diagnostic specificity.1,23,24
The significance of our findings is limited by the retrospective
nature of this study and its single-centre sample size. Neverthe-
less, as our selection was based on both clinical and histopatho-
logical findings, with the exclusion of patients with other
background diseases, we believe our data represent accurate
observations. Larger prospective multi-centre studies are
required to validate our findings and to establish a generally
acceptable cut-off value of this ratio.
In conclusion, our results suggest that NLR is a potential
prognostic marker for systemic involvement in adult IgAV and
can be used to identify patients at risk of developing extracuta-
neous manifestations. In addition, we also found that increased
pretreatment NLR correlated with the severity of the systemic
involvement. Whether this ratio may permit the design of
prospective therapeutic studies remains to be determined.
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